The Affiliated Hospital of Guiyang Medical College/The Affiliated Cancer Hospital of Guiyang Medical College/Guizhou Cancer Hospital
Welcome,         Profile    Billing    Logout  
 12 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jin, Feng
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Recruiting
2
30
RoW
SI-B001
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/25
06/25
NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Recruiting
2
30
RoW
SI-B001, Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/25
06/25
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
2
152
RoW
PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Bristol-Myers Squibb
Nasopharyngeal Carcinoma
04/24
03/26

Download Options